Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Cancer Discovery
Oliver WeigertDavid M Weinstock

Abstract

The relative timing of genetic alterations that contribute to follicular lymphoma remains unknown. We analyzed a donor-recipient pair who both developed grade 2/3A follicular lymphoma 7 years after allogeneic transplantation and donor lymphocyte infusions. Both patients harbored identical BCL2/IGH rearrangements also present in 1 in 2,000 cells in the donor lymphocyte infusion, and the same V(D)J rearrangement, which underwent somatic hypermutation both before and after clonal divergence. Exome sequencing of both follicular lymphomas identified 15 shared mutations, of which 14 (including alterations in EP300 and KLHL6) were recovered from the donor lymphocyte infusion by ultra-deep sequencing (average read coverage, 361,723), indicating acquisition at least 7 years before clinical presentation. Six additional mutations were present in only one follicular lymphoma and not the donor lymphocyte infusion, including an ARID1A premature stop, indicating later acquisition during clonal divergence. Thus, ultrasensitive sequencing can map clonal evolution within rare subpopulations during human lymphomagenesis in vivo. For the first time, we define the molecular ontogeny of follicular lymphoma during clonal evolution in vivo. By using u...Continue Reading

References

Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R AndersonD D Weisenburger
Nov 5, 1999·Methods in Molecular Biology·S Rozen, H Skaletsky
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K E SummersJ Fitzgibbon
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Apr 26, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Olga Sala-TorraJerald P Radich
Oct 18, 2006·The Journal of Experimental Medicine·Sandrine RoullandBertrand Nadel
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Feb 16, 2007·The New England Journal of Medicine·Louis M Staudt
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beth ChristianKristie A Blum
Oct 5, 2010·Cancer Research·K-John J CheungDouglas E Horsman
Oct 15, 2010·The New England Journal of Medicine·Kimberly C WiegandDavid G Huntsman
Oct 19, 2010·Nucleic Acids Research·Simon A ForbesP Andrew Futreal
Mar 11, 2011·Nature·Laura PasqualucciRiccardo Dalla-Favera
Jul 29, 2011·Nature·Ryan D MorinMarco A Marra

❮ Previous
Next ❯

Citations

Oct 2, 2012·The Journal of Clinical Investigation·Robert KridelRandy D Gascoyne
Sep 6, 2013·Haematologica·Philip M Kluin
Oct 29, 2013·Haematologica·Emilie MamessierBertrand Nadel
May 3, 2014·Haematologica·Emilie MamessierBertrand Nadel
Nov 11, 2014·The Journal of Clinical Investigation·Stéphanie SungaleeSandrine Roulland
Aug 15, 2014·Leukemia & Lymphoma·Andreas KreftRalf Georg Meyer
Jan 1, 2015·Leukemia & Lymphoma·Carsten HirtCharles S Rabkin
Dec 2, 2015·Leukemia·E LeichUNKNOWN German Low Grade Lymphoma Study Group (GLSG)
Oct 30, 2014·Annals of the New York Academy of Sciences·Andrew G Evans, Laura M Calvi
Apr 14, 2015·Nature Immunology·Luisa CimminoIannis Aifantis
Aug 8, 2012·Blood·Oliver Weigert, David M Weinstock
Dec 8, 2015·Hematology·Jane N Winter, LoAnn C Peterson
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine RoullandBertrand Nadel
Jan 21, 2017·Epigenetics : Official Journal of the DNA Methylation Society·Koorosh KorfiJude Fitzgibbon
Apr 11, 2017·Journal of Internal Medicine·P GhiaF K Stevenson
Nov 16, 2017·American Journal of Clinical Pathology·Christian A KunderYasodha Natkunam
Aug 22, 2017·Nature Cell Biology·Sarah J HortonBrian J P Huntly
Apr 19, 2018·Blood·Ralf Küppers, Freda K Stevenson
May 9, 2018·Current Opinion in Hematology·James A HewardJude Fitzgibbon
Jan 17, 2019·Cell Cycle·Jaewoo ChoiLuca Busino
Mar 16, 2019·Immunological Reviews·Laura Pasqualucci
Mar 1, 2014·Leukemia·W Hiddemann, B D Cheson
May 9, 2014·Current Opinion in Hematology·Michael R Green, Ash A Alizadeh
May 3, 2016·Current Opinion in Hematology·Jessica OkosunJude Fitzgibbon
Jun 8, 2015·Current Opinion in Hematology·Pierre MilpiedSandrine Roulland
Mar 13, 2020·Blood·Sandrine Roulland
May 20, 2020·Leukemia & Lymphoma·Lucy PickardJessica Okosun
Jun 25, 2020·British Journal of Haematology·Lucía Prieto-TorresSocorro M Rodríguez-Pinilla
May 12, 2015·Médecine sciences : M/S·Sandrine Roulland, Bertrand Nadel
Apr 6, 2017·Hematological Oncology·Randy D GascoyneEmanuele Zucca
Dec 14, 2019·Nature Reviews. Disease Primers·Antonino CarboneJude Fitzgibbon
Oct 28, 2017·British Journal of Haematology·Matthew L Chase, Philippe Armand
Jan 4, 2018·Blood Advances·Simon Husby, Kirsten Grønbæk
Feb 10, 2018·Nature Reviews. Cancer·Sarah HuetGilles Salles
Jun 13, 2014·Cancer Discovery·Frederik DammOlivier A Bernard
Mar 12, 2021·British Journal of Haematology·Emil KumarJessica Okosun
Jan 17, 2017·Seminars in Hematology·Max JanSiddhartha Jaiswal
Jun 8, 2021·HemaSphere·Gabriel BrisouSandrine Roulland

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.